Science Translational Medicine: 'Creating Hope Act' incentivizes pediatric drug R&D

January 19, 2011

Recent legislative and regulatory actions make great strides toward establishing much needed incentives for pharmaceutical companies and others to develop and test more medications for pediatric rare diseases, including pediatric cancers, according to commentary by experts from Children's National Medical Center. The commentary appears in the January 19 issue of Science Translational Medicine.

"Pediatricians who treat children with serious and life-threatening diseases often find themselves face to face with the inadequacies of pediatric drug development," write Edward Connor, MD, director of the Office of Innovation Development and Investigational Therapeutics at Children's National Medical Center, and Pablo Cure, MD, MPH, Laboratory for Entrepreneurial Achievement in Pediatrics (LEAP) Scholar in the Office of Innovation Development and Investigational Therapeutics.

In a previous commentary for this journal, Dr. Connor noted that despite the fact that children make up nearly 40 percent of the world's population, little research is done to test the effects of "adult therapies" on children, who have unique needs requiring tailored care more sophisticated than merely smaller doses of adult therapeutics. The demand for pediatric drugs, especially those for like childhood cancer, is relatively low compared to the demand for adult drugs, as fewer children develop rare and serious illnesses. To maximize efficacy and return on investment, pharmaceutical developers sometimes focus their efforts on therapeutics that address illnesses common to larger populations.

Pediatric specialists frequently have to prescribe therapeutics for children "off-label" because many common drugs and devices for treating diseases are only tested in adults but are necessary for the treatment of children. Research, however, has shown repeatedly that drugs and devices for adults can impact children differently.

According to the authors, the Creating Hope Act of 2010 that is pending before Congress recognizes the importance of stimulating pediatric drug development. It updates the existing Priority Voucher for Neglected Diseases Program to include rare and serious diseases of childhood. That program offers a financial incentive to companies developing drugs for neglected diseases.

"Although government support is critical," the authors continued, "it is not sufficient to produce products…for use in children. Incentive programs like the Creating Hope Act and other approaches designed to motivate for children are also needed. Our investment in biomedical research is providing returns, and we need to assure that children, the most vulnerable among us, benefit from this investment as well."

Explore further: Docs try to close info gap on kids' meds

Related Stories

Docs try to close info gap on kids' meds

November 23, 2007

Ten years after the U.S. government began trying to ensure children's prescription drugs were safe, doctors still have little information to guide them.

Study exposes need for pediatric cardiac devices

March 30, 2009

Nearly two-thirds of children who undergo routine interventional cardiology procedures -- those involving a catheter to treat structural disorders of the heart -- may be receiving treatment with a device that's being used ...

Adverse drug events: a large burden in pediatric care

September 28, 2009

( -- An 11year national analysis at Children's Hospital Boston shows that side effects or accidental overdoses of medications are a common complication of outpatient care in children, generating more than half ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

( -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.